<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261898</url>
  </required_header>
  <id_info>
    <org_study_id>060036</org_study_id>
    <secondary_id>06-DK-0036</secondary_id>
    <nct_id>NCT00261898</nct_id>
  </id_info>
  <brief_title>Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity</brief_title>
  <official_title>Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      OBJECTIVE: Obesity and chronic sleep deprivation have both become increasingly pervasive
      medical problems in recent years. The prevalence of adult obesity has doubled over the past
      30 years and continues to increase. In addition, industrial societies attach an economic
      value to maximizing the waking period to the longest tolerable limit by sleeping as little as
      possible. Average sleep time has decreased over the last century by 2 hours. Chronically
      sleeping less has been associated with increased weight, endocrine and metabolic health risks
      including glucose intolerance, cardiovascular disease, and mortality. The possibility that
      the current epidemic of obesity and metabolic health risks may be partially related to
      insufficient sleep is now being recognized. The objective of this proof-of-concept controlled
      trial is to investigate the impact of increasing sleep time in chronically sleep-deprived,
      obese subjects.

      STUDY POPULATION: 18-50 year old, obese (BMI 30-50) men and premenopausal women, chronically
      sleep deprived, recruited from the Baltimore-Washington metropolitan area. Chronic sleep
      deprivation will be verified by the use of sleep logs and the use of actigraphy before entry
      into the study. Secondary causes of sleep deprivation such as insomnia, psychological
      (depression), and medical conditions associated with poor sleep quality (including
      obstructive sleep apnea) will be exclusionary criteria.

      DESIGN: This is a randomized, 12-month duration, comparison-controlled clinical trial of an
      extension of sleep up to approximately 7 hours and 30 minutes (Intervention Group) or
      continuation of habitual short sleep schedule (Comparison Group). The proposed treatment is
      an educational and behavioral intervention aimed at increasing sleep in a non-pharmacological
      fashion. The main analysis of the study will be to determine if additional sleep will result
      in a significant difference in body weight at the end of 12 months between the Intervention
      Group and the Comparison Group. In addition, we would like to establish whether 12 months of
      additional sleep will result in: a) a decreased prevalence of metabolic syndrome; and b)
      changes in the endocrine profile (i.e. inducing changes in leptin [increase] and ghrelin
      [decrease] opposite to the changes associated with chronic sleep deprivation). At the end of
      the 12-month intervention study (Phase 1, Efficacy Randomized Phase Study), all participants
      will be given information about the potential benefit of more sleep and encouraged to
      increase sleep time. Health teaching about proper nutrition and adequate exercise will also
      be provided at that time to the Intervention and Comparison Groups. All participants will be
      evaluated 6 months later to assess the effects of this intervention in a real-life situation,
      and offered participation in a three-year extension with semi-annual visits (Phase 2,
      Effectiveness 3 Year Follow-Up Phase Study), for which matched external comparison subjects
      will also be recruited ad hoc.

      OUTCOME PARAMETERS: body weight, average number of hours of sleep/night, fasting glucose and
      insulin, oral glucose tolerance test, leptin, ghrelin, adiponectin, other relevant endocrine
      and anthropometric measures, body composition, various metabolic parameters, food intake,
      energy expenditure, and quality of life measures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE: Obesity and chronic sleep deprivation have both become increasingly pervasive
      medical problems in recent years. The prevalence of adult obesity has doubled over the past
      30 years and continues to increase. In addition, industrial societies attach an economic
      value to maximizing the waking period to the longest tolerable limit by sleeping as little as
      possible. Average sleep time has decreased over the last century by 2 hours. Chronically
      sleeping less has been associated with increased weight, endocrine and metabolic health risks
      including glucose intolerance, cardiovascular disease, and mortality. The possibility that
      the current epidemic of obesity and metabolic health risks may be partially related to
      insufficient sleep is now being recognized. The objective of this proof-of-concept controlled
      trial is to investigate the impact of increasing sleep time in chronically sleep-deprived,
      obese subjects.

      STUDY POPULATION: 18-50 year old, obese (BMI 29-55) men and premenopausal women, chronically
      sleep deprived, recruited from the Baltimore-Washington metropolitan area. Chronic sleep
      deprivation will be verified by the use of sleep logs and the use of actigraphy before entry
      into the study. Secondary causes of sleep deprivation such as insomnia, psychological
      (depression), and medical conditions associated with poor sleep quality (including
      obstructive sleep apnea) will be exclusionary criteria.

      DESIGN: This is a randomized, 12-month duration, comparison-controlled clinical trial of an
      extension of sleep up to approximately 7 hours and 30 minutes (Intervention Group) or
      continuation of habitual short sleep schedule (Comparison Group). The proposed treatment is
      an educational and behavioral intervention aimed at increasing sleep in a non-pharmacological
      fashion. The main analysis of the study will be to determine if additional sleep will result
      in a significant difference in body weight at the end of 12 months between the Intervention
      Group and the Comparison Group. In addition, we would like to establish whether 12 months of
      additional sleep will result in: a) a decreased prevalence of metabolic syndrome; and b)
      changes in the endocrine profile (i.e. inducing changes in leptin [increase] and ghrelin
      [decrease] opposite to the changes associated with chronic sleep deprivation). At the end of
      the 12-month intervention study (Phase 1, Efficacy [Randomized Phase] Study), all
      participants will be given information about the potential benefit of more sleep and
      encouraged to increase sleep time. Health teaching about proper nutrition and adequate
      exercise will also be provided at that time to the Intervention and Comparison Groups. All
      participants will be evaluated 6 months later to assess the effects of this intervention in a
      real-life situation, and offered participation in a three-year extension with semi-annual
      visits (Phase 2, Effectiveness [3 Year Follow-Up Phase] Study), for which matched external
      comparison subjects will also be recruited ad hoc.

      OUTCOME PARAMETERS: body weight, average number of hours of sleep/night, fasting glucose and
      insulin, oral glucose tolerance test, leptin, ghrelin, adiponectin, other relevant endocrine
      and anthropometric measures, body composition, various metabolic parameters, food intake,
      energy expenditure, and quality of life measures.

      The study was terminated early for reasons of apparent futility of continuing accrual of
      participants according to the original study plan. The decision was based on independent
      analysis of data acquired during the initial feasibility phase and from interim analysis of
      early results that failed to document objectively the achievement of substantive and
      meaningful differences between experimental and control groups with respect to amounts of
      sleep extension, changes in metabolic parameters, or changes in weight. Feasibilities of
      achieving objective and substantive differences in these parameters were integral to the
      methodology of the original study plan and required to meet the statistical power
      calculations for the controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study has been terminated. (Interim analysis of preliminary results indicated the need for
    protocol re-design).
  </why_stopped>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">239</enrollment>
  <condition>Obesity</condition>
  <condition>Chronic Sleep Deprivation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Increase sleep</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

             18 to 50 year old obese men and premenopausal women

        BMI between 29-55

        Chronically (for more than 6 months) sleep-deprived, defined as sleeping on a regular basis
        less than or equal to approximately 6-1/2 hours/night by history and objective devices
        (wrist activity monitors and sleep logs).

        INCLUSION CRITERIA: External comparison subjects for extension of Effectiveness Study must
        meet the criteria above.

        EXCLUSION CRITERIA:

        Diagnosed sleep disorders including:

          -  Chronic insomnia

          -  Untreated sleep disordered breathing (sleep apnea at a level of severity [using
             standardized criteria for measurement], or diagnosed UARS [upper airway resistance
             syndrome] that would impair the ability to increase sleep duration [Intervention
             Group] or maintain sleep duration [Comparison Group]. CPAP treatment that has been in
             place for 3 months or more and improves sleep is acceptable).

          -  Restless leg syndrome or periodic limb movement disorder

          -  Parasomnias (including REM sleep behavior disorders, confusional arousals, sleep
             terrors, sleepwalking, sleep violence)

          -  Primary bruxism is allowed as long as it does not interfere with the ability to sleep
             an additional 90 minutes a night

          -  Narcolepsy

          -  Central apnea.

        Unstable weight (voluntary losses in BMI greater than 5% over the past 6 months); currently
        being enrolled in a weight loss program

        Untreated or uncontrolled diabetes

        Severe uncontrolled hypertension

        Other chronic organ disease diagnosis including:

          -  COPD

          -  Chronic cardiac arrhythmia requiring treatments

          -  Gastro-esophageal disorders associated with sleep-related symptoms.

        Medications

          -  chronic use of prescription or over-the-counter medications known to affect sleep
             (e.g., systemic steroids, NSAIDs)

          -  current anticonvulsant therapy

        Chronic fatigue syndrome and fibromyalgia

        Acromegaly, hypothyroidism (unless on a stable replacement dose of thyroid hormone),
        Cushing disease or other endocrine disorders known to affect sleep

        Poorly controlled major depression (subjects who have been on a stable pharmacological
        antidepressant treatment for 3 months and are in remission without substantial weight gain
        are eligible).

        Other current DSM-IV diagnoses, including:

          -  Eating disorders such as bulimia nervosa and binge eating disorder

          -  Anxiety disorders such as PTSD and panic attacks

          -  Mania

          -  Schizophrenia.

        Medication and substance abuse such as excessive alcohol consumption or drug abuse or
        dependence that may pose a threat to compliance

        Being a rotating worker, shift worker (working evenings or nights), or long distance
        commuter (more than approximately 90 minutes each way), traveling frequently outside of
        time zone; being in an occupation that may require special vigilance such as driving a
        truck, bus, or cab; operating heavy machinery; being a pilot or air traffic controller

        Being likely to move to a different geographical area during the study

        Having a sleep partner that would make compliance with study requirements difficult

        Pregnancy and lactation

        Menopause

        Chronic excessive caffeine use (habitual intake of more than 500 mg/day)

        Any condition that in the opinion of the principal investigator makes study participation
        and compliance problematic.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Cizza, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cizza G, Skarulis M, Mignot E. A link between short sleep and obesity: building the evidence for causation. Sleep. 2005 Oct;28(10):1217-20.</citation>
    <PMID>16295203</PMID>
  </reference>
  <reference>
    <citation>Cizza G, Romagni P, Lotsikas A, Lam G, Rosenthal NE, Chrousos GP. Plasma leptin in men and women with seasonal affective disorder and in healthy matched controls. Horm Metab Res. 2005 Jan;37(1):45-8.</citation>
    <PMID>15702439</PMID>
  </reference>
  <reference>
    <citation>Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004 Jun;89(6):2583-9. Review.</citation>
    <PMID>15181027</PMID>
  </reference>
  <reference>
    <citation>Gangwisch JE, Malaspina D, Boden-Albala B, Heymsfield SB. Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. Sleep. 2005 Oct;28(10):1289-96.</citation>
    <PMID>16295214</PMID>
  </reference>
  <reference>
    <citation>Hasler G, Buysse DJ, Klaghofer R, Gamma A, Ajdacic V, Eich D, RÃ¶ssler W, Angst J. The association between short sleep duration and obesity in young adults: a 13-year prospective study. Sleep. 2004 Jun 15;27(4):661-6.</citation>
    <PMID>15283000</PMID>
  </reference>
  <reference>
    <citation>Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004 Dec 7;141(11):846-50.</citation>
    <PMID>15583226</PMID>
  </reference>
  <reference>
    <citation>Wehr TA. Effect of seasonal changes in daylength on human neuroendocrine function. Horm Res. 1998;49(3-4):118-24. Review.</citation>
    <PMID>9550111</PMID>
  </reference>
  <reference>
    <citation>Cizza G, Piaggi P, Rother KI, Csako G; Sleep Extension Study Group. Hawthorne effect with transient behavioral and biochemical changes in a randomized controlled sleep extension trial of chronically short-sleeping obese adults: implications for the design and interpretation of clinical studies. PLoS One. 2014 Aug 20;9(8):e104176. doi: 10.1371/journal.pone.0104176. eCollection 2014.</citation>
    <PMID>25141012</PMID>
  </reference>
  <reference>
    <citation>Cizza G, Marincola P, Mattingly M, Williams L, Mitler M, Skarulis M, Csako G. Treatment of obesity with extension of sleep duration: a randomized, prospective, controlled trial. Clin Trials. 2010 Jun;7(3):274-85. doi: 10.1177/1740774510368298. Epub 2010 Apr 27.</citation>
    <PMID>20423926</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2005</study_first_submitted>
  <study_first_submitted_qc>December 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2005</study_first_posted>
  <last_update_submitted>November 3, 2015</last_update_submitted>
  <last_update_submitted_qc>November 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <keyword>Sleep Deprivation</keyword>
  <keyword>Obesity</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Hormones</keyword>
  <keyword>Public Health</keyword>
  <keyword>Overweight</keyword>
  <keyword>Sleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

